ACTM 838
Alternative Names: ACTM-838Latest Information Update: 22 Jul 2024
Price :
$50 *
At a glance
- Originator Actym Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Interleukin-15 expression stimulants; STING1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 05 Jun 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Monotherapy) in Australia (IV) (NCT06336148)
- 30 May 2024 Actym Therapeutics plans a phase-I trial for Solid tumours (Second-line or greater therapy) in the US and Australia in April 2024 (NCT06336148)
- 30 May 2024 US FDA approves IND application for ACTM 838 in Solid tumors